Cargando…

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX

Homoharringtonine (HHT) and imatinib have a synergistic effect in the clinical treatment of chronic myeloid leukemia (CML). The purpose of the present study was to explore the underlying mechanisms by which HHT enhanced imatinib sensitivity. K562 CML cells were treated with HHT and imatinib separate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jingjing, Wei, Bin, Shi, Yuye, Lu, Xueying, Ding, Yihan, Wang, Chunling, Li, Yufeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755169/ https://www.ncbi.nlm.nih.gov/pubmed/31432109 http://dx.doi.org/10.3892/mmr.2019.10539

Ejemplares similares

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines
por: Wang, Qian, et al.
Publicado: (2017)

KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia
por: Zhang, Chengwan, et al.
Publicado: (2021)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
por: Zhang, Xiuyan, et al.
Publicado: (2023)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Baicalein Inhibits Progression of Gallbladder Cancer Cells by Downregulating ZFX
por: Liu, Tian-Yu, et al.
Publicado: (2015)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
por: Kim, Soo Jung, et al.
Publicado: (2014)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
por: Jelinek, Jaroslav, et al.
Publicado: (2011)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia
por: Wang, Xiao, et al.
Publicado: (2023)

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
por: Tracy, Alexis, et al.
Publicado: (2022)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients
por: Delord, Marc, et al.
Publicado: (2013)

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway
por: Zhang, Xiaobo, et al.
Publicado: (2017)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2022)

A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib
por: Park, Mi-Jung, et al.
Publicado: (2014)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells
por: Chen, Zhiwei, et al.
Publicado: (2021)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis
por: Stephens, Jennifer, et al.
Publicado: (2010)

Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients
por: Thiant, S, et al.
Publicado: (2017)

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy
por: Woywod, Clemens, et al.
Publicado: (2017)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
por: Bandyopadhyay, Shovik, et al.
Publicado: (2017)

CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia
por: Guerra, Borja, et al.
Publicado: (2016)

Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib
por: Ali, Naveed, et al.
Publicado: (2016)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6g2ob0rtcg20sud1kuvf4hfp21